162 related articles for article (PubMed ID: 28379024)
1. [Comments on current guidelines of type 2 diabetes mellitus treatment].
Martinka E
Vnitr Lek; 2017; 63(3):211-217. PubMed ID: 28379024
[TBL] [Abstract][Full Text] [Related]
2. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Aronson R
Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
Gerstein H; Jaeschke R
Pol Arch Med Wewn; 2016 Oct; 126(10):803-805. PubMed ID: 27872459
[No Abstract] [Full Text] [Related]
4. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
Scheen AJ; Paquot N
Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
Chudleigh RA; Bain S
Expert Opin Drug Saf; 2017 May; 16(5):627-635. PubMed ID: 28387138
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.
White JR
Ann Pharmacother; 2015 May; 49(5):582-98. PubMed ID: 25712444
[TBL] [Abstract][Full Text] [Related]
7. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
Ingelfinger JR; Rosen CJ
N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
[No Abstract] [Full Text] [Related]
8. After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
Schatz H
Exp Clin Endocrinol Diabetes; 2016 Sep; 124(8):459-460. PubMed ID: 27701709
[TBL] [Abstract][Full Text] [Related]
9. [Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type].
Prázný M; Slíva J
Vnitr Lek; 2015 Feb; 61(2):175-8. PubMed ID: 25813264
[TBL] [Abstract][Full Text] [Related]
10. London buses: A cardiovascular outcome trial equivalent?
Grant PJ
Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
[No Abstract] [Full Text] [Related]
11. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Laubner K; Seufert J
Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455
[TBL] [Abstract][Full Text] [Related]
12. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult.
Thompson AM; Linnebur SA; Vande Griend JP; Saseen JJ
Consult Pharm; 2014 Feb; 29(2):110-23. PubMed ID: 24513421
[TBL] [Abstract][Full Text] [Related]
13. Obesity Week 2016 Annual Meeting.
Marathe PH; Dove AE; Gao HX; Odeh SA; Close KL
J Diabetes; 2017 Mar; 9(3):215-218. PubMed ID: 27883282
[No Abstract] [Full Text] [Related]
14. [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
Forst T; Plum-Mörschel L; Weber MM
Internist (Berl); 2017 Mar; 58(3):293-302. PubMed ID: 28120022
[TBL] [Abstract][Full Text] [Related]
15. Obesity in 2015: Advances in managing obesity.
Dixon JB
Nat Rev Endocrinol; 2016 Feb; 12(2):65-6. PubMed ID: 26729038
[No Abstract] [Full Text] [Related]
16. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Scheen AJ; Piérard L; Krzesinski JM; Paquot N
Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
[TBL] [Abstract][Full Text] [Related]
17. Impact of empagliflozin in patients with diabetes and heart failure.
Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
[TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
Scheen AJ; Wallemacq C; Jandrain B; Ernest P
Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE
Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
[TBL] [Abstract][Full Text] [Related]
20. Glycemic control and the heart: it matters how you get there.
Bloomgarden Z
J Diabetes; 2016 Jul; 8(4):453-4. PubMed ID: 26990043
[No Abstract] [Full Text] [Related]
[Next] [New Search]
